Final psychedelics guidance suggests FDA is 'receptive' to helping companies succeed. July 14, 2026 | The agency's finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like Compass Pathways, whose psilocybin-based therapy for treatment-resistant depression could win approval as early as this year. The FDA released final guidance Monday for developers of psychedelic drugs, an update of its draft recommendations from 2023 that provides an initial framework for future regulatory action. "FDA's final guidance on psychedelics suggests the agency remains receptive to helping sponsors succeed," Jefferies said in a note to investors on Monday. The announcement comes on the heels of positive data from Compass Pathways and Definium Therapeutics, both frontrunners in the psychedelics space. The final version of the guidance also follows President Donald Trump's executive order earlier this year urging U.S. health agencies to allow an established path to approval for drugs such as psilocybin, MDMA and even ibogaine. Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could "wipe out the SSRIs" if safety and durability hold up. July 9, 2026 Much of the feedback the FDA received from stakeholders following the draft release concerned clinical trial design, particularly around distinguishing the therapeutic mechanism of the drug candidate from other factors that might come with the psychedelic effects. Not much has changed from the draft version three years ago. But the latest iteration, released Monday, grants more flexibility for sponsors bringing psychedelic compounds to the agency's doorstep, both in terms of modeling abuse potential and measuring overall effectiveness. The guidance states that abuse potential studies may not be necessary when an assessment has already been "well-characterized from extensive clinical studies and robust epidemiological data exist," adding that sponsors should reach out to the FDA if they "believe there is sufficient existing data that the human abuse potential is already well-characterized." Placebo trials of psychedelic drugs are complicated by the noticeable effects of the drugs on the patient, particularly those who have taken them before. The guidance suggests additional blinding mechanisms and durability tests to help ensure reliable data. The final guidance "largely reaffirm[s] the existing framework while signaling a preference for blinded durability data," H.C. Wainwright said in a Tuesday note to investors. The guidance also sets the bar for a clinical hold in cases that include risk of illness or injury, including supervision by a trained healthcare provider following administration. Companies like Compass and Definium, among others, stand to benefit from the guidance. Compass is developing a psilocybin-based therapy, COMP360, for treatment-resistant depression, for which it received an expedited Commissioner's National Priority Voucher review in April following Trump's executive order. Last week, new data from a Phase 3 trial of treatment-resistant depression showed that the treatment worked quickly and durably, further supporting an ongoing rolling submission for COMP360. While the FDA did not announce the recipient names of the Commissioner's National Priority Vouchers, the agency's descriptions of the awarded products match those in development at Compass Pathways, Transcend Therapeutics and Usona Institute. April 24, 2026 Definium's formulation of LSD, meanwhile, showed "profound" efficacy in a late-stage trial last month, results that Definium CEO Rob Barrow said "bring us one step closer to potentially delivering a transformative new treatment option as we advance toward FDA submission." The FDA will hold a public hearing regarding therapeutic use of psychedelic drugs on Sept. 14. Jefferies called the timing and "exact intention" behind the meeting "curious," wondering if it "obviates the need for pot'l future AdComs unless the clinical data are controversial" - particularly as COMP360 could be approved by the end of this year. The final guidance could also be particularly apt as Health Secretary Robert F. Kennedy moves forward with his initiative to get Americans to stop taking another class of psychiatric drugs, selective serotonin reuptake inhibitors (SSRIs). Earlier this month, mental health professionals met with federal health officials to discuss clinical guidance they hope will lead to deprescribing of SSRIs, STAT News reported on Monday. The Trump administration's push for psychedelic therapy approval has been a mixed bag in scientific circles, generating public buzz for much needed novel mental health treatments while also setting off alarms that the benefits are exaggerated. "Ultimately," Jefferies said, "a friendlier regulatory environment should make psychedelics a more investable space." With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner's National Priority Vouchers this week, it's full speed ahead for psychedelics. But will sidestepping normal regulatory protocols actually be a net negative for the field? April 22, 2026

Compass Pathways (NASDAQ:CMPS) Advances Psilocybin Therapy for treatment-resistant depression. Jul 07, 2026 Market News FMPCompass Pathways (NASDAQ:CMPS) Advances Psilocybin Therapy for Treatment-Resista... * Compass Pathways (NASDAQ:CMPS) is making significant progress with its COMP360 psilocybin therapy for treatment-resistant depression, supported by positive Phase 3 clinical trial results. * Analyst firm Oppenheimer has reiterated an "Outperform" rating for Compass Pathways, citing strong data and improved launch prospects for its main therapy. * The company's long-term data reinforces a planned 2027 launch, with the stock showing recent positive movement and a market capitalization of approximately $1.24 billion. Compass Pathways (NASDAQ:CMPS) is a mental health care company. It focuses on developing innovative therapies for difficult-to-treat mental health conditions. The company is known for its research into psilocybin therapy, particularly its proprietary synthetic psilocybin formulation, COMP360, for treatment-resistant depression (TRD). On July 7, 2026, analyst firm Oppenheimer restated its "Outperform" rating for Compass Pathways when the stock was priced at $12.64. As highlighted by TheFly, Oppenheimer's confidence comes from recent data that it believes improves the company's future launch prospects for its main therapy. This positive outlook is supported by 26-week results from Compass Pathways' second Phase 3 trial, COMP006. The clinical trial, which studies COMP360 for TRD, confirms the treatment has a rapid and lasting effect. These findings are consistent with a previous Phase 3 trial, COMP005, which also showed a good safety profile. The long-term data from the study, involving nearly 600 patients, reinforces Compass Pathways' planned launch timeline for 2027. This suggests the company is on track to bring its synthetic psilocybin therapy to market. Following the news, Compass Pathways is trading at $12.94, an increase of 0.74% for the day. The stock has a 52-week range between $3.34 and $15.40. The company currently has a market capitalization, or total market value, of approximately $1.24 billion, with a trading volume of about 10.54 million shares. Market news and analyst rating coverage Gordon Thompson covers analyst rating changes, price-target updates, and company news for the FMP blog. His work focuses on summarizing the latest broker actions and market developments into accessible, data-driven updates for investors and analysts. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP

COMPASS Pathways has appointed Kathleen Tregoning to its Board of Directors, adding commercialisation and policy expertise as the psychedelic therapy developer approaches potential regulatory approval. Tregoning will join the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. Tregoning brings experience from Cerevel Therapeutics, Sanofi and Biogen in corporate affairs, commercial strategy and late-stage biotech scaling. The appointment follows COMPASS's April 2026 FDA decision granting rolling NDA review for its COMP360 treatment for treatment-resistant depression. The pre-revenue company currently operates at a loss and faces regulatory risk. Analysts project US$193.1 million revenue by 2029, though the most pessimistic forecasts suggest only US$59.5 million, highlighting divergent views on the company's commercial prospects.